Compare TE Connectivity plc Ordinary Shares (TEL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TE Connectivity plc Ordinary Shares vs Tango Therapeutics Inc. — how do they compare? TE Connectivity plc Ordinary Shares trades at $210.29 (market cap $60.87B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 16.2× Tango Therapeutics Inc.'s market cap, and TE Connectivity plc Ordinary Shares pays a 1.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold TE Connectivity plc Ordinary Shares for 0 Days and Tango Therapeutics Inc. for 0 Days on average.
| TEL | TNGX | |
|---|---|---|
Market Cap | $60.87B | $3.75B |
Volume | 1,389,840 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $249.00 | $32.90 |
52-Week Low | $195.84 | $7.50 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $65.26B | $2.77B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TE Connectivity (TEL) trades at $215.92, down 0.63% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 15.61% net margin, and improving cash flow. Recent analyst upgrades highlight growth potential as the company prepares for Q4 2026 earnings on October 28.
TEL offers solid investment appeal with 23.54% ROE and 48% analyst buy ratings, though near-term volatility may persist. The $253.22 consensus target implies 17% upside, supported by operational strength and dividend stability. Key risks include market sensitivity and execution challenges in competitive electronics components sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
